bioquiddity logo link to home page
AUGUST 2015
    BioQuiddity and Lee’s Pharmaceutical Enter Agreement to Jointly Commercialize Two Infusion Pharmaceuticals in China, Taiwan, Hong Kong, and Macau
JULY 2015
    BioQuiddity Appoints
    Daniel Tassé to its Board
    of Directors
MAY 2015
    BioQuiddity Enters Into an Exclusive License and Supply Agreement to Commercialize Two Ready‐to‐Use Infusion Products in the United States
JULY 2014
    Cipla and BioQuiddity announce
    EU Commercial Partnership for OneDose-ReadyfusOR for Post-Surgical Pain Management
DECEMBER 2013
    N. W. (Bill) Jasper Jr. elected to
    Board of Directors

N. W. (Bill) Jasper Jr. elected to Board of Directors


N. W. (Bill) Jasper Jr. was elected to the Board of Directors of BioQuiddity Incorporated in December 2013. The retired president and Chief Executive Officer of Dolby Laboratories led the transformation of Dolby from a small technology innovator in 1979 to its initial public offering in 2005. The international technology giant reported sales of nearly $1 billion in 2012.

Mr. Jasper, an active resident of Sonoma California, said: “The worldwide demand for safe, effective healthcare has increased costs to patients, providers and payers. BioQuiddity has designed a proprietary infusion system platform to reduce costs and improve quality of life for patients at home, in hospitals, nursing facilities, and in civic disasters, the battlefield, and developing countries.”

Joshua Kriesel PhD, President and CEO of BioQuiddity stated: “Mr. Jasper’s experience in corporate governance, finance, technology transformation and licensing adds to the Company’s distinguished Board of Directors and Medical Advisors.”

Mr. Jasper earned an MBA from the University of California Berkeley and a B.S. in Industrial Engineering from Stanford University.